Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2020 Dec 17;106(5):1457–1460. doi: 10.3324/haematol.2020.269878

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2021 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 2. — Distribution of major immune cell types in patients with COVID-19 according to the type of hematological cancer and outcome. Patients were classified according to the pre-malignant vs. malignant stage of the disease, tumor type and outcome. Grey boxes represent the distribution of coronavirus disease 2019 (COVID-19) patients without blood cancer, and dots correspond to hematological patients. Black asterisks indicate significant differences between patients without and with hematological tumor, and red asterisks represent significant differences between alive and deceased patients with hematological cancer. No significant differences were observed between pre-malignant and malignant stages. *P<0.05; **P<0.01. AML: acute myeloid leukemia; MBL: monoclonal B-cell lymphocytosis; MDS: myelodysplastic syndrome; MGUS: monoclonal gammopathy of undetermined significance; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma. NK: natural killer.